Abstract:BackgroundAlthough nontremor and tremor Part 3 Movement Disorder Society–Unified Parkinson's Disease Rating Scale items measure different impairment domains, their distinct progression and drug responsivity remain unstudied longitudinally. The total score may obscure important time-based and treatment-based changes occurring in the individual domains. ObjectiveUsing the unique advantages of item response theory (IRT), we developed novel longitudinal unidimensional and multidimensional models to investigate nontremor and tremor changes occurring in an interventional Parkinson's disease (PD) study. MethodWith unidimensional longitudinal IRT, we assessed the 33 Part 3 item data (22 nontremor and 10 tremor items) of 336 patients with early PD from the STEADY-PD III (Safety, Tolerability, and Efficacy Assessment of Isradipine for PD, placebo vs. isradipine) study. With multidimensional longitudinal IRT, we assessed the progression rates over time and treatment (in overall motor severity, nontremor, and tremor domains) using Markov Chain Monte Carlo implemented in Stan. ResultsRegardless of treatment, patients showed significant but different time-based deterioration rates for total motor, nontremor, and tremor scores. Isradipine was associated with additional significant deterioration over placebo in total score and nontremor scores, but not in tremor score. Further highlighting the 2 separate latent domains, nontremor and tremor severity changes were positively but weakly correlated (correlation coefficient, 0.108). ConclusionsLongitudinal IRT analysis is a novel statistical method highly applicable to PD clinical trials. It addresses limitations of traditional linear regression approaches and previous IRT investigations that either applied cross-sectional IRT models to longitudinal data or failed to estimate all parameters simultaneously. It is particularly useful because it can separate nontremor and tremor changes both over time and in response to treatment interventions.

A novel longitudinal rank-sum test for multiple primary endpoints in clinical trials: Applications to neurodegenerative disorders

A non-parametric U-statistic testing approach for multi-arm clinical trials with multivariate longitudinal data

Multivariate Rank-Based Analysis of Multiple Endpoints in Clinical Trials: A Global Test Approach

Analytic Challenges in Clinical Trials in Early Alzheimers Disease

Cognitive Biomarker Prioritization in Alzheimer's Disease using Brain Morphometric Data

Sparse item testing of clinical scales in neurology trials to alleviate burden to patients

Application of a Novel Endpoint Staging Framework: Proof of Concept in the AMBAR Study

Efficiency of multivariate tests in trials in progressive supranuclear palsy

Cognitive biomarker prioritization in Alzheimer’s Disease using brain morphometric data

Novel Approach to Movement Disorder Society–Unified Parkinson's Disease Rating Scale Monitoring in Clinical Trials: Longitudinal Item Response Theory Models

A Novel Joint Brain Network Analysis Using Longitudinal Alzheimer’s Disease Data

A Statistical Framework for Assessing the Relationship between Biomarkers and Clinical Endpoints in Alzheimer's Disease

High-Throughput Clinical Trial Emulation with Real World Data and Machine Learning: A Case Study of Drug Repurposing for Alzheimer's Disease

A Nonparametric Global Win Probability Approach to the Analysis and Sizing of Randomized Controlled Trials With Multiple Endpoints of Different Scales and Missing Data: Beyond O'Brien–Wei–Lachin

The relative efficiency of time-to-progression and continuous measures of cognition in pre-symptomatic Alzheimer's

A Design For Survival Studies: A Multi-regional Trial With Unrecognized Heterogeneity

Projection-based two-sample inference for sparsely observed multivariate functional data

A Multi-Dimensional Comparison of Alzheimer's Disease Neurodegenerative Biomarkers

Using Real-World Data to Rationalize Clinical Trials Eligibility Criteria Design: A Case Study of Alzheimer's Disease Trials.

Identification and inference for subgroups with differential treatment efficacy from randomized controlled trials with survival outcomes through multiple testing

Unlocking Cognitive Analysis Potential in Alzheimer's Disease Clinical Trials: Investigating Hierarchical Linear Models for Analyzing Novel Measurement Burst Design Data